Bicycle Therapeutics Plc ADR (NASDAQ: BCYC) on Friday, plunged -3.13% from the previous trading day, before settling in for the closing price of $23.44. Within the past 52 weeks, BCYC’s price has moved between $12.54 and $28.67.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 38.55% annually for the last half of the decade. The company achieved an average annual earnings per share of 40.34%. With a float of $65.91 million, this company’s outstanding shares have now reached $69.02 million.
In an organization with 284 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 86.54%, operating margin of -595.3%, and the pretax margin is -521.23%.
Bicycle Therapeutics Plc ADR (BCYC) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Bicycle Therapeutics Plc ADR is 4.51%, while institutional ownership is 55.59%. The most recent insider transaction that took place on Oct 03 ’24, was worth 71,499. In this transaction CHIEF EXECUTIVE OFFICER of this company sold 3,212 shares at a rate of $22.26, taking the stock ownership to the 380,864 shares. Before that another transaction happened on Oct 03 ’24, when Company’s CHIEF PROD & SUPPLY CHAIN OFF sold 247 for $22.26, making the entire transaction worth $5,498. This insider now owns 22,398 shares in total.
Bicycle Therapeutics Plc ADR (BCYC) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 40.34% per share during the next fiscal year.
Bicycle Therapeutics Plc ADR (NASDAQ: BCYC) Trading Performance Indicators
Bicycle Therapeutics Plc ADR (BCYC) is currently performing well based on its current performance indicators. A quick ratio of 17.13 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 42.40.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.30, a number that is poised to hit -0.88 in the next quarter and is forecasted to reach -3.49 in one year’s time.
Technical Analysis of Bicycle Therapeutics Plc ADR (BCYC)
Let’s dig in a bit further. During the last 5-days, its volume was 0.47 million. That was better than the volume of 0.36 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 3.24%. Additionally, its Average True Range was 1.31.
During the past 100 days, Bicycle Therapeutics Plc ADR’s (BCYC) raw stochastic average was set at 36.60%, which indicates a significant increase from 1.16% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 29.74% in the past 14 days, which was lower than the 61.31% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $24.21, while its 200-day Moving Average is $22.87. However, in the short run, Bicycle Therapeutics Plc ADR’s stock first resistance to watch stands at $23.58. Second resistance stands at $24.46. The third major resistance level sits at $24.93. If the price goes on to break the first support level at $22.24, it is likely to go to the next support level at $21.77. The third support level lies at $20.89 if the price breaches the second support level.
Bicycle Therapeutics Plc ADR (NASDAQ: BCYC) Key Stats
Market capitalization of the company is 1.57 billion based on 47,501K outstanding shares. Right now, sales total 26,980 K and income totals -180,660 K. The company made 9,360 K in profit during its latest quarter, and -39,810 K in sales during its previous quarter.
